Comparison of Anesthetic Efficacy of Dexmedetomidine and Epinephrine With Lidocaine in Irreversible Pulpitis
Irreversible Pulpitis
About this trial
This is an interventional treatment trial for Irreversible Pulpitis
Eligibility Criteria
Inclusion Criteria:
- 18-50 years of age.
- Patient willing to participate in the study.
- Mature permanent mandibular first and second molars exhibiting signs of symptomatic irreversible pulpitis as assessed by history, cold and electric pulp tests.
- Absence of periapical lesions on radiographic examination.
Exclusion Criteria:
- Patient not ready to participate in the study voluntarily
- Clinical history or electrocardiographic evidence of heart block, Ischaemic heart disease
- Asthma, Sleep apnoea syndrome.
- Impaired liver, renal or mental function.
- Alcohol consumption in excess of 28 units per week.
- Chronic sedative and analgesic user and those having known allergy to study drugs
- Patients with severe periodontal disease.
- Patients unable to return for recall appointments
- Signs or symptoms of external /internal resorption, furcation or periapical radiolucency, swelling, or sinus tract.
- Negative response to cold and electric pulp tests.
- Antibiotic or analgesic intake within past 24 hours before treatment
Sites / Locations
- Post Graduate Institute of Dental Sciences
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
1.8 ml Lignocaine plus adrenaline
3.6 ml Lignocaine plus adrenaline
1.8 ml Lignocaine plus dexmedetomidine
3.6 ml Lignocaine plus dexmedetomidine
The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of 2% inj lignocaine with adrenaline 1:80000.
The study subjects will receive conventional inferior alveolar nerve block with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.
conventional inferior alveolar nerve block with1.8 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
conventional inferior alveolar nerve block with3.6 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.